Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

Lower ICS dose effect on symptoms and rescue medication use of indacaterol/glycopyrronium/mometasone (IND/GLY/MF) medium-dose vs salmeterol/fluticasone (Sal/Flu) high-dose plus tiotropium (Tio): ARGON study

Christian Gessner, Oliver Kornmann, Jorge Maspero, Richard Van Zyl-Smit, Matthias Krüll, Agustín Sojo, Anna Salina, Pritam Gupta, Lorena Garcia Conde
European Respiratory Journal 2020 56: 2634; DOI: 10.1183/13993003.congress-2020.2634
Christian Gessner
1Universitätsklinikum Leipzig, Germany POIS Leipzig GbR, Leipzig, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: ch.gessner@pois-le.de
Oliver Kornmann
2IKF Pneumologie Frankfurt, Clinical Research Centre Respiratory Diseases, Frankfurt, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jorge Maspero
3Allergy and Respiratory Research Unit, Fundación CIDEA, Buenos Aires, Argentina
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Van Zyl-Smit
4Division of Pulmonology and UCT Lung Institute, Department of Medicine University of Cape Town, Cape Town, South Africa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Krüll
5Institut für Allergie- und Asthmaforschung Berlin (IAAB) GbR, Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Agustín Sojo
6Sección de Neumología, Complejo Hospitalario Universitario de Cáceres, Cáceres, Spain
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Salina
7Novartis Pharma AG, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Pritam Gupta
8Novartis Healthcare Pvt. Ltd, Hyderabad, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lorena Garcia Conde
7Novartis Pharma AG, Basel, Switzerland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Article Information

vol. 56 no. suppl 64
DOI 
https://doi.org/10.1183/13993003.congress-2020.2634

Published By 
European Respiratory Society
Print ISSN 
0903-1936
Online ISSN 
1399-3003
History 
  • Published online October 28, 2020.

Copyright & Usage 
Copyright ©the authors 2020

Author Information

  1. Christian Gessner1⇑,
  2. Oliver Kornmann2,
  3. Jorge Maspero3,
  4. Richard Van Zyl-Smit4,
  5. Matthias Krüll5,
  6. Agustín Sojo6,
  7. Anna Salina7,
  8. Pritam Gupta8 and
  9. Lorena Garcia Conde7
  1. 1Universitätsklinikum Leipzig, Germany POIS Leipzig GbR, Leipzig, Germany
  2. 2IKF Pneumologie Frankfurt, Clinical Research Centre Respiratory Diseases, Frankfurt, Germany
  3. 3Allergy and Respiratory Research Unit, Fundación CIDEA, Buenos Aires, Argentina
  4. 4Division of Pulmonology and UCT Lung Institute, Department of Medicine University of Cape Town, Cape Town, South Africa
  5. 5Institut für Allergie- und Asthmaforschung Berlin (IAAB) GbR, Berlin, Germany
  6. 6Sección de Neumología, Complejo Hospitalario Universitario de Cáceres, Cáceres, Spain
  7. 7Novartis Pharma AG, Basel, Switzerland
  8. 8Novartis Healthcare Pvt. Ltd, Hyderabad, India
  1. Christian Gessner, Universitätsklinikum Leipzig, Germany POIS Leipzig GbR, Leipzig, Germany. E-mail: ch.gessner{at}pois-le.de

Article usage

Article usage: October 2020 to May 2023

AbstractFullPdf
Oct 2020500
Nov 20205000
Dec 202010500
Jan 20212600
Feb 20211200
Mar 2021900
Apr 20212300
May 20213100
Jun 20212900
Jul 20218100
Aug 20213300
Sep 20212000
Oct 20212300
Nov 20212300
Dec 20212600
Jan 20222500
Feb 20222900
Mar 20222700
Apr 20221500
May 2022800
Jun 20221300
Jul 20222800
Aug 20221300
Sep 20222300
Oct 20221600
Nov 20221000
Dec 2022800
Jan 2023300
Feb 2023700
Mar 20231200
Apr 2023300
May 2023700

Altmetrics

Previous
Back to top
Vol 56 Issue suppl 64 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Lower ICS dose effect on symptoms and rescue medication use of indacaterol/glycopyrronium/mometasone (IND/GLY/MF) medium-dose vs salmeterol/fluticasone (Sal/Flu) high-dose plus tiotropium (Tio): ARGON study
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Lower ICS dose effect on symptoms and rescue medication use of indacaterol/glycopyrronium/mometasone (IND/GLY/MF) medium-dose vs salmeterol/fluticasone (Sal/Flu) high-dose plus tiotropium (Tio): ARGON study
Christian Gessner, Oliver Kornmann, Jorge Maspero, Richard Van Zyl-Smit, Matthias Krüll, Agustín Sojo, Anna Salina, Pritam Gupta, Lorena Garcia Conde
European Respiratory Journal Sep 2020, 56 (suppl 64) 2634; DOI: 10.1183/13993003.congress-2020.2634

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Lower ICS dose effect on symptoms and rescue medication use of indacaterol/glycopyrronium/mometasone (IND/GLY/MF) medium-dose vs salmeterol/fluticasone (Sal/Flu) high-dose plus tiotropium (Tio): ARGON study
Christian Gessner, Oliver Kornmann, Jorge Maspero, Richard Van Zyl-Smit, Matthias Krüll, Agustín Sojo, Anna Salina, Pritam Gupta, Lorena Garcia Conde
European Respiratory Journal Sep 2020, 56 (suppl 64) 2634; DOI: 10.1183/13993003.congress-2020.2634
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • RCT Abstract - Randomized, double-blind, placebo-controlled, phase III clinical trial with MV130, a sublingual bacterial immunotherapy to prevent COPD exacerbations
  • The effectiveness of anti-IL5 biologics is comparable in previous-smokers and never-smokers with severe asthma
  • Late Breaking Abstract - First-time assessment of efficacy of candidate vaccine to prevent acute exacerbations of chronic obstructive pulmonary disease (AECOPD): multicentre, randomised, controlled, observer-blind phase 2b trial
Show more Airway pharmacology and treatment

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society